{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Epinephrine (Drug)", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Prices (Fares, Fees and Rates)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Generic Brands and Products", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Inventions and Patents", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Lobbying and Lobbyists", "name": "subject", "rank": "6", "is_major": "N"}, {"value": "Mylan Inc", "name": "organizations", "rank": "7", "is_major": "Y"}, {"value": "Antitrust Laws and Competition Issues", "name": "subject", "rank": "8", "is_major": "N"}, {"value": "Medicare", "name": "subject", "rank": "9", "is_major": "Y"}, {"value": "Editorials", "name": "subject", "rank": "10", "is_major": "Y"}], "web_url": "http://www.nytimes.com/2016/09/22/opinion/the-epipen-outrage-continues.html", "document_type": "article", "byline": {"person": [], "original": "By THE EDITORIAL BOARD", "organization": "THE EDITORIAL BOARD"}, "type_of_material": "Editorial", "multimedia": [{"url": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg", "legacy": {"wide": "images/2016/09/22/opinion/22thu2/22thu2-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg", "legacy": {"xlarge": "images/2016/09/22/opinion/22thu2/22thu2-articleLarge.jpg", "xlargeheight": "600", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 600}, {"url": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/09/22/opinion/22thu2/22thu2-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Opinion", "word_count": "526", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs.", "pub_date": "2016-09-22T04:00:00+0000", "news_desk": "Editorial", "headline": {"kicker": "Editorial", "print_headline": "The EpiPen Outrage Continues", "main": "The EpiPen Outrage Continues", "content_kicker": "Editorial"}, "print_page": "30", "snippet": "It\u2019s time for Congress to stop letting pharmaceutical companies get away with price gouging on lifesaving drugs....", "_id": "57e32b7995d0e021d7987a0a", "slideshow_credits": null, "abstract": "Editorial rebukes Congress for merely censuring Mylan's chief executive for significantly raising price of EpiPens instead of directly addressing issue of rising drug costs; calls for empowering Medicare to negotiate prices with drug makers and making it easier for generic drug makers to bring cheaper version to market."}